Long‐Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry
Open Access
- 29 September 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70208
Abstract
Background: Dupilumab‐associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab‐treated atopic dermatitis (AD) patients. We investigated the effect of long‐term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins. Methods: This prospective study included moderate‐to‐severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020–October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow‐up (≥ 2 years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a ≥ 3‐point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid. Results: Forty‐four patients were included. OSD was present in 90.9% ( n = 40/44) of patients at all visits. DAOSD occurred in 22.7% ( n = 10/44) of patients; 40.0% ( n = 4/10) persisted or newly developed at last follow‐up. Tear break‐up time decreased while tear production increased. Tear fluid dupilumab levels and AD‐related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow‐up compared to baseline. Mucin5AC (MUC5AC) production in CK19‐CD45‐MUC5AC + cells decreased at week 28 and remained stable at last follow‐up. Conclusion: OSD remained common during long‐term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD‐related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.Keywords
Funding Information
- Eli Lilly and Company
- Almirall
- LEO Pharma
- Pfizer
This publication has 28 references indexed in Scilit:
- Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisJAMA Dermatology, 2024
- Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysisClinical and Translational Allergy, 2024
- Dupilumab in Adults With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2024
- Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJournal of the American Academy of Dermatology, 2024
- High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface diseaseClinical and Translational Allergy, 2023
- Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2021
- Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitisThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Biological functions of tear filmExperimental Eye Research, 2020
- Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyJournal of the American Academy of Dermatology, 2020
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitisJournal of the American Academy of Dermatology, 2017